15,283 Shares in Cytokinetics, Incorporated $CYTK Acquired by AMI Asset Management Corp

AMI Asset Management Corp bought a new stake in Cytokinetics, Incorporated (NASDAQ:CYTK) during the third quarter, HoldingsChannel.com reports. The firm bought 15,283 shares of the biopharmaceutical company’s stock, valued at approximately $840,000.

A number of other hedge funds have also recently made changes to their positions in CYTK. EverSource Wealth Advisors LLC lifted its stake in shares of Cytokinetics by 723.7% in the second quarter. EverSource Wealth Advisors LLC now owns 766 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 673 shares during the period. Hantz Financial Services Inc. raised its position in Cytokinetics by 2,872.7% in the 2nd quarter. Hantz Financial Services Inc. now owns 1,308 shares of the biopharmaceutical company’s stock valued at $43,000 after buying an additional 1,264 shares during the last quarter. UMB Bank n.a. increased its stake in Cytokinetics by 37.8% in the 2nd quarter. UMB Bank n.a. now owns 1,593 shares of the biopharmaceutical company’s stock valued at $53,000 after buying an additional 437 shares during the last quarter. Farther Finance Advisors LLC raised its stake in shares of Cytokinetics by 68.4% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,115 shares of the biopharmaceutical company’s stock worth $61,000 after purchasing an additional 453 shares during the period. Finally, GAMMA Investing LLC raised its holdings in shares of Cytokinetics by 109.4% in the 3rd quarter. GAMMA Investing LLC now owns 1,472 shares of the biopharmaceutical company’s stock worth $81,000 after purchasing an additional 769 shares during the period.

Insider Activity at Cytokinetics

In other Cytokinetics news, EVP Andrew Callos sold 1,042 shares of the stock in a transaction on Monday, December 8th. The shares were sold at an average price of $65.96, for a total transaction of $68,730.32. Following the completion of the transaction, the executive vice president owned 50,660 shares in the company, valued at $3,341,533.60. This trade represents a 2.02% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Fady Ibraham Malik sold 2,200 shares of Cytokinetics stock in a transaction on Tuesday, December 16th. The stock was sold at an average price of $61.24, for a total transaction of $134,728.00. Following the completion of the transaction, the executive vice president directly owned 138,552 shares of the company’s stock, valued at $8,484,924.48. The trade was a 1.56% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 168,494 shares of company stock valued at $10,811,018 over the last quarter. 2.70% of the stock is currently owned by insiders.

Cytokinetics News Summary

Here are the key news stories impacting Cytokinetics this week:

• Positive Sentiment: FDA approval of Myqorzo (aficamten) turns Cytokinetics into a commercial‑stage cardiology biotech and establishes a new revenue runway — a principal driver of investor enthusiasm. Article Title
• Positive Sentiment: Multiple brokers raised price targets or reiterated Buy/Outperform views (examples: Citizens/JMP raised its PT to $88; Morgan Stanley maintained an overweight), supporting further upside expectations. Article Title
• Positive Sentiment: Unusually high call‑option volume suggests traders are positioning for additional near‑term upside. Article Title
• Positive Sentiment: Institutional accumulation reported in recent quarters (new and increased stakes by several funds) provides a supportive ownership base for the rally. Article Title
• Neutral Sentiment: Needham and other brokers reiterated positive ratings (Needham maintained its Buy) — supportive but largely reaffirmative rather than new catalysts. Article Title
• Neutral Sentiment: Reported short‑interest data in December shows zero shares (likely a reporting/data anomaly), so short‑interest signals are currently uninformative.
• Negative Sentiment: Insider selling: director Wendell Wierenga sold 20,000 shares at about $66.14 (Dec. 22), trimming his stake ~38% — a potential near‑term negative for sentiment. SEC Filing
• Negative Sentiment: HC Wainwright trimmed Q4 and FY2025 EPS forecasts slightly (small downward revisions to losses per share), signaling modestly weaker near‑term profitability expectations despite maintaining a Buy and a $136 target. Article Title

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on the company. Needham & Company LLC increased their target price on Cytokinetics from $72.00 to $84.00 and gave the stock a “buy” rating in a research report on Monday. Evercore ISI raised their price objective on Cytokinetics from $60.00 to $80.00 and gave the company an “outperform” rating in a research note on Wednesday, September 3rd. Stifel Nicolaus upped their target price on Cytokinetics from $87.00 to $96.00 and gave the company a “buy” rating in a report on Tuesday, September 2nd. B. Riley restated a “buy” rating and set a $90.00 price target (up from $80.00) on shares of Cytokinetics in a research report on Monday, November 10th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Cytokinetics in a research note on Tuesday, October 21st. Fifteen analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $83.61.

Cytokinetics Price Performance

NASDAQ CYTK opened at $63.86 on Friday. Cytokinetics, Incorporated has a 1-year low of $29.31 and a 1-year high of $70.98. The business has a 50 day simple moving average of $62.99 and a two-hundred day simple moving average of $49.31. The stock has a market capitalization of $7.81 billion, a PE ratio of -10.15 and a beta of 0.58.

Cytokinetics (NASDAQ:CYTK) last posted its earnings results on Wednesday, November 5th. The biopharmaceutical company reported ($1.54) EPS for the quarter, beating analysts’ consensus estimates of ($1.59) by $0.05. The firm had revenue of $1.94 million for the quarter, compared to the consensus estimate of $6.05 million. During the same quarter in the prior year, the company posted ($1.36) earnings per share. The firm’s revenue was up 318.1% compared to the same quarter last year. On average, analysts anticipate that Cytokinetics, Incorporated will post -5.24 EPS for the current fiscal year.

Cytokinetics Profile

Cytokinetics, Inc is a late‐stage biopharmaceutical company focused on the discovery and development of novel small‐molecule therapeutics that modulate muscle function. Founded in 1998 and headquartered in South San Francisco, California, the company applies its proprietary insights in muscle biology to address diseases characterized by impaired muscle performance. Its research spans both cardiac and skeletal muscle targets, aiming to deliver innovative medicines for conditions with significant unmet medical need.

The company’s most advanced program, omecamtiv mecarbil, is being evaluated for the treatment of heart failure by enhancing cardiac muscle contractility.